The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
This study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor, on paclitaxel (PTX) tumor distribution and antitumor activity in xenograft models of human ovarian carcinoma...
Հիմնական հեղինակներ: | Cesca, M, Frapolli, R, Berndt, A, Scarlato, V, Richter, P, Kosmehl, H, D'Incalci, M, Ryan, A, Giavazzi, R |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
2009
|
Նմանատիպ նյութեր
-
Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts
: Edmond Auzenne, և այլն
Հրապարակվել է: (2007-06-01) -
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
: Wachsberger, P, և այլն
Հրապարակվել է: (2009) -
Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
: Choi, S, և այլն
Հրապարակվել է: (2008) -
Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma
: Hideki Iwamoto, և այլն
Հրապարակվել է: (2011-03-01) -
Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts
: Demuytere J, և այլն
Հրապարակվել է: (2024-01-01)